Arcus Biosciences Inc (NYSE: RCUS): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Gilead and Arcus Announce Amended Collaboration and Equity Investment.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

RCUS belongs to the Healthcare sector of the NYSE while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $15.22 and fluctuated between $15.40 as its day high and $14.76 as its day low. The current market capitalization of Arcus Biosciences Inc is $1.14B. A total of 0.68 million shares were traded on the day, compared to an average of 822.41K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, RCUS has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 21,521 shares. Over the last 12 months, there were 8 BUYs and 15 SELLs from insiders. Insiders purchased 1,057,600 shares during that period but sold 215,878.

In the most recent transaction, GILEAD SCIENCES, INC. bought 15,238,095 shares of RCUS for 21.00 per share on Jan 29. After the transaction, the 10% Owner now owns 30,061,124 company shares. In a previous transaction on Jan 02, Jaen Juan C. sold 6,975 shares at 20.09 per share. RCUS shares that President owns now total 1,215,265.

Among the insiders who sold shares, Goeltz II Robert C. disposed of 2,004 shares on Jan 02 at a per-share price of $20.00. This resulted in the Chief Financial Officer holding 51,831 shares of RCUS after the transaction. In another insider transaction, Jarrett Jennifer sold 21,521 shares at $17.76 per share on Dec 22. Company shares held by the Chief Operating Officer now total 258,878.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, RCUS has a high of $25.47 and a low of $12.95.

As of this writing, RCUS has an earnings estimate of -$1.02 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.82 per share and a lower estimate of -$1.21. The company reported an EPS of -$1.04 in the last quarter, which was 5.50% higher than expectations of -$1.1.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. RCUS’s latest balance sheet shows that the firm has $499.00M in Cash & Short Term Investments as of fiscal 2021. There were $116.89M in debt and $166.00M in liabilities at the time. Its Book Value Per Share was $6.95, while its Total Shareholder’s Equity was $842.00M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RCUS is Buy with a score of 4.80.

Most Popular

Related Posts